CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Avexitidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04652479
NCT04652479Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia

Dr. Tracey McLaughlin, MD·interventional·Posted Dec 3, 2020·Updated Jun 9, 2023

In Brief

A Phase 2 clinical trial evaluating Avexitide for Acquired Hyperinsulinemic Hypoglycemia. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The primary goal of this study is to evaluate the safety and efficacy of two different dosing regimens of an investigational drug called Avexitide in treating low blood sugar in patients with Acquired Hyperinsulinemic Hypoglycemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Hyperinsulinemic Hypoglycemia
CountriesUnited States
CollaboratorsEiger BioPharmaceuticals

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 3, 2020
Enrollment StartJun 21, 2021
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.6 years ago

Interventions

Avexitidedrug

Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor